Cover Image
市場調查報告書

PharmaEssentia Corporation:產品平台分析

PharmaEssentia Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 219742
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
PharmaEssentia Corporation:產品平台分析 PharmaEssentia Corporation - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 33 Pages
簡介

PharmaEssentia Corporation 是正在開發治療原發性血小板增多症,癌症,慢性骨髓性白血病,肝炎,骨髓纖維化,真性多血症等骨髓增生性腫瘤的藥物候補之生物製藥公司。

本報告提供PharmaEssentia Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

PharmaEssentia Corporation的基本資料

PharmaEssentia Corporation概要

  • 主要資訊
  • 企業資料

PharmaEssentia Corporation:R&D概要

  • 主要的治療範圍

PharmaEssentia Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

PharmaEssentia Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

PharmaEssentia Corporation:藥物簡介

  • (paclitaxel + HM30181A)
  • peginterferon alfa-2b
  • P-1116
  • PEG-FSH
  • pegfilgrastim

PharmaEssentia Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

PharmaEssentia Corporation:最近的開發平台趨勢

PharmaEssentia Corporation:暫停中的計劃

PharmaEssentia Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07323CDB

Summary

Global Markets Direct's, 'PharmaEssentia Corporation - Product Pipeline Review - 2015', provides an overview of the PharmaEssentia Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of PharmaEssentia Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of PharmaEssentia Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of PharmaEssentia Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the PharmaEssentia Corporation's pipeline products

Reasons to buy

  • Evaluate PharmaEssentia Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of PharmaEssentia Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the PharmaEssentia Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of PharmaEssentia Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of PharmaEssentia Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of PharmaEssentia Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • PharmaEssentia Corporation Snapshot
    • PharmaEssentia Corporation Overview
    • Key Information
    • Key Facts
  • PharmaEssentia Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • PharmaEssentia Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • PharmaEssentia Corporation - Pipeline Products Glance
    • PharmaEssentia Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • PharmaEssentia Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • PharmaEssentia Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • PharmaEssentia Corporation - Drug Profiles
    • (paclitaxel + HM30181A)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ropeginterferon ALFA-2B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • P-1116
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-FSH
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Beta Thalassemia and Sickle Cell Anemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • PharmaEssentia Corporation - Pipeline Analysis
    • PharmaEssentia Corporation - Pipeline Products by Target
    • PharmaEssentia Corporation - Pipeline Products by Route of Administration
    • PharmaEssentia Corporation - Pipeline Products by Molecule Type
    • PharmaEssentia Corporation - Pipeline Products by Mechanism of Action
  • PharmaEssentia Corporation - Recent Pipeline Updates
  • PharmaEssentia Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • PharmaEssentia Corporation, Key Information
  • PharmaEssentia Corporation, Key Facts
  • PharmaEssentia Corporation - Pipeline by Indication, 2015
  • PharmaEssentia Corporation - Pipeline by Stage of Development, 2015
  • PharmaEssentia Corporation - Monotherapy Products in Pipeline, 2015
  • PharmaEssentia Corporation - Combination Treatment Modalities in Pipeline, 2015
  • PharmaEssentia Corporation - Partnered Products in Pipeline, 2015
  • PharmaEssentia Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • PharmaEssentia Corporation - Phase III, 2015
  • PharmaEssentia Corporation - Phase II, 2015
  • PharmaEssentia Corporation - Phase I, 2015
  • PharmaEssentia Corporation - Preclinical, 2015
  • PharmaEssentia Corporation - Pipeline by Target, 2015
  • PharmaEssentia Corporation - Pipeline by Route of Administration, 2015
  • PharmaEssentia Corporation - Pipeline by Molecule Type, 2015
  • PharmaEssentia Corporation - Pipeline Products by Mechanism of Action, 2015
  • PharmaEssentia Corporation - Recent Pipeline Updates, 2015
  • PharmaEssentia Corporation, Other Locations

List of Figures

  • PharmaEssentia Corporation - Pipeline by Top 10 Indication, 2015
  • PharmaEssentia Corporation - Pipeline by Stage of Development, 2015
  • PharmaEssentia Corporation - Monotherapy Products in Pipeline, 2015
  • PharmaEssentia Corporation - Partnered Products in Pipeline, 2015
  • PharmaEssentia Corporation - Pipeline by Top 10 Target, 2015
  • PharmaEssentia Corporation - Pipeline by Top 10 Route of Administration, 2015
  • PharmaEssentia Corporation - Pipeline by Top 10 Molecule Type, 2015
  • PharmaEssentia Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top